Chande Nilesh, Marshall John K, Seow Cynthia H, Sandborn William J, Parker Claire E, Nelson Sigrid, Feagan Brian G
*Division of Gastroenterology, Department of Medicine, Western University, London, Ontario, CA; †Division of Gastroenterology, McMaster University, Hamilton, Ontario, CA; ‡Division of Gastroenterology, Departments of Medicine and Community Health Sciences, University of Calgary, Alberta, CA; §Division of Gastroenterology, University of California San Diego, La Jolla, CA; ‖Robarts Clinical Trials, Inc, Robarts Research Institute, Western University, London, Ontario, CA; Departments of ¶Medicine, and **Epidemiology and Statistics, Western University, London, Ontario, CA.
Inflamm Bowel Dis. 2015 Dec;21(12):2948-57. doi: 10.1097/MIB.0000000000000631.
Although multiple innovative treatments of inflammatory bowel disease have become available, research continues to refine the value of existing drug therapies for Crohn's disease and ulcerative colitis. What can Cochrane reviews tell us about evolving applications for traditional agents in inflammatory bowel disease? A Cochrane Collaboration symposium held at the 2014 Digestive Diseases Week annual meeting addressed this question. This article reviews the data presented at that session.
尽管多种治疗炎症性肠病的创新疗法已经出现，但研究仍在不断完善现有药物疗法对克罗恩病和溃疡性结肠炎的价值。Cochrane系统评价能告诉我们关于传统药物在炎症性肠病中不断演变的应用情况有哪些呢？在2014年消化系统疾病周年度会议上举行的一次Cochrane协作研讨会探讨了这个问题。本文回顾了该会议上展示的数据。
